

Please note: the substantive content of the 2026 NRI Roadmap Survey begins at Question 20 (with prior questions dealing with administrative and other information).

As such all submissions that are published include the responses submitted from Question 20 onwards only.

Q20.

Part 2: Research themes

2.1 NRI comprises the assets, facilities and associated expertise to support leading-edge research and innovation in Australia and is accessible to publicly and privately funded users across Australia and internationally. We are seeking your input on possible directions for future national-level investment - i.e., where the requirements are of such scale and importance that national-level collaboration and coordination are essential.

The [2021 Roadmap](#) used a challenge framework to support NRI planning and investment. With this in mind, consider likely future research trends in the next 5 - 10 years, and with respect to one or more of the 8 challenge areas identified in the 2021 Roadmap as listed below:

- describe emerging research directions and the associated critical research infrastructure requirements that are either not currently available at all, or not at sufficient scale and
- describe current national infrastructure requirements that you anticipate will no longer fit the definition of NRI in 5-10 years.

Do not limit your commentary to NCRIS funded capabilities.

Q21.

Resources Technology and Critical Minerals Processing

Q22.

Food and Beverage

The increasing focus on food security in an environmentally sustainable way will see increased focus on maximizing crop yields byThe application of species specific growth promoters. These will be small molecule organic molecules that will interact with native and engineered protein targets to increase plant-fungi interaction for increased nutrient uptake. The discovery and translation of these plant growth promoters will benefit from a national NMR facility.

Q23.

Medical Products

While the use of biologics will continue to be explored across all disease states, the current predominance of small molecule therapeutics is unlikely to change. The discovery of new small molecule therapeutics is likely to be enhanced by a national phenotype testing facility (like the NCI's 60 line cancer screening facility). This would and the discovery of therapies with new modes of action.

Q24.

Defence

The COVID pandemic taught us that supply lines are a critical risk across all sectors. Australia must become self sufficient in the production of high energy materials for defence purposes. The invention of new environmentally sustainable degradable, and increased stability high energy materials would benefit from a national high energy materials characterisation and testing facility.

Q25.

Recycling and Clean Energy

Q26.

Space

This aligns with my comments on defence.

Q27.

Environment and Climate

Q28.

Frontier Technologies and Modern Manufacturing

Q29.

2.2 The 2024 statement of National Science and Research Priorities (NSRPs) includes outcomes linked to each priority to assist in identifying critical research needed in the next 5 to 10 years.

Consider the priority statements and, with respect to one or more of the 5 priority areas as listed below:

- describe emerging research directions and the associated critical research infrastructure requirements that are either not currently available at all, or
- not at sufficient scale and describe current national infrastructure requirements that you anticipate will no longer fit the definition of NRI in 5-10 years.

Do not limit your commentary to NCRIS funded capabilities, and where relevant, refer to the underpinning outcomes and research identified in the NSRPs document.

Q30.

Transitioning to a net zero future

Q31.

Supporting healthy and thriving communities

Q32.

Elevating Aboriginal and Torres Strait Islanders knowledge systems

Q33.

Protecting and restoring Australia's environment

Q34.

Building a secure and resilient nation

Local R&D and manufacturing will enable of nation to be insulated from global stocks. This will be increasingly important in medical therapies and food production

Q35.

2.3 The case for a new NRI capability, or enhancements to existing capabilities, typically emerges through advocacy from research communities clustering around rigorously identified needs and goals. Such a concept could respond to a requirement for novel or expanded capacity within a domain, or across domains, and must be such that it could only be made available with national-level investment.

If you have identified such a requirement, briefly describe the need, the proposed infrastructure capability, the medium-term goals, impacted research communities, and the timeframe over which you advocate its establishment. Your response can include links to relevant existing reports.

A national NMR facility (perhaps a hub and spokes model) will support advances in many nationally critical areas of research including biomedical and food production. These technologies are an absolute requirement for all molecular research, increasingly out of the price range of research institutes and universities, but lack the glamour of being 'breakthrough' technology. They support research and discovery as a critical tool.

Q36.

Part 3: Industry perspectives

This section is seeking input specifically from industry-based respondents. Other respondents can skip this section.

Recommendation 6 of the [2021 Roadmap](#) related to improvements in industry engagement with NRI. To complement work on this topic that has occurred since then, we are seeking additional advice on NRI requirements as perceived by current or potential industry-based users.

Q37.

3.1 Have you (or your organisation) interreacted with or used Australia's NRI?

☒ Yes

☐ No

Q38.

3.2 If so, please briefly outline the NRI capabilities you (or your organisation) have interacted with or used. Do not limit your response to NCRIS capabilities.

Personally, I've made use of the NCI.

Q39.

3.3 Please indicate your (one or more) primary reasons for interacting with NRI:

☐ For expertise or advice

☐ Access to research resources or products

- ☒ Access to equipment for research
- ☐ Access to equipment for operational reasons
- ☐ Help in translating research
- ☐ Access to data
- ☐ Support for clinical trials
- ☐ Other (please specify)

Q40.

3.4 If you answered no, please indicate your (one or more) primary reasons:

This question was not displayed to the respondent.

Q41.

Part 4: Other comments

4.1 Please elaborate on any of your above responses or add any other comments relevant to the development of the 2026 Roadmap. Your response can include reference or links to existing reports that you recommend be considered during the 2026 Roadmap development process.

Q49.

4.2 Optional Document Attachment.

Note: Our strong preference is that answers are provided against the relevant questions in the survey. However, this file upload option is available for submissions in file format, where needed. Please ensure the document includes your name or organisation.